Use of immune checkpoint inhibitors to treat cancer is growing rapidly — and with it, so is a common side effect: colitis. A small new study suggests fecal transplants might help, but experts caution the potential treatment needs to be studied much more.

Immune checkpoint inhibitors (ICIs) are a class of immunotherapy drugs that unleash the immune system to attack cancer cells. For some some patients on the drugs, colitis — inflammation in the colon that can cause bleeding, pain, diarrhea, and dehydration — can become so severe that some patients have to pause their cancer treatment while clinicians try to get the inflammation in check.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy